Abstract 467P
Background
To investigate the application effect of evidence-based concept of cluster management model in oncology nutrition case management.
Methods
Experimental observation was conducted on 60 cases of oncology patients, and the study period was from August 2021 to August 2022. In the process of nutritional case management of the patients, 30 cases were included in the observation group to carry out the evidence-based concept of the cluster management mode; the other 30 patients belonged to the control group and received routine nursing guidance. Observe and compare the nutritional status and nursing satisfaction of the two groups of patients.
Results
Before nursing care, the nutritional status (S-Amy (blood amylase), U-Amy (urine amylase), Alb (serum albumin), etc.) of the patients in the two groups was assessed, and no significant difference existed between the observation group and the control group (P > 0.05); after the implementation of different nursing care measures, the nutritional status of the patients in the two groups was compared again and found to be significantly different, and that the nutritional status of the patients in the observation group was significantly better ( P＜0.05). The results of patients' satisfaction with nursing interventions showed that the observation group (96.7%) was significantly higher than the control group (70.0%), with a significant difference (P < 0.05).
Conclusions
In the nutritional case management of oncology patients, the implementation of the evidence-based concept of cluster management mode can significantly improve the nutritional status of patients, help patients to strengthen their physical fitness, which is beneficial to the control of patients' conditions, and the patients' satisfaction with nursing care is high, which is worthy of promotion.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
143P - Ablation combined with tislelizumab in treating hepatocellular carcinoma: A phase II trial
Presenter: Yangxun Pan
Session: Poster Display
Resources:
Abstract
144P - Integrated clinical and genomic models using machine-learning methods to predict the efficacy of paclitaxel-based chemotherapy in patients with advanced gastric cancer from K-MASTER project
Presenter: Jwa Hoon Kim
Session: Poster Display
Resources:
Abstract
145P - Tislelizumab (TIS) + chemotherapy (Chemo)/chemoradiotherapy (CRT) as neoadjuvant treatment for resectable esophageal squamous cell carcinoma (R-ESCC)
Presenter: Longqi Chen
Session: Poster Display
Resources:
Abstract
146P - Phase (ph) Ib results of bemarituzumab (BEMA) added to capecitabine/oxaliplatin (CAPOX) or S-1/oxaliplatin (SOX) with or without nivolumab (NIVO) for previously untreated advanced gastric/gastroesophageal junction cancer (G/GEJC): FORTITUDE-103 study
Presenter: Keun-Wook Lee
Session: Poster Display
Resources:
Abstract
147P - Four-year overall survival (OS) update from the phase III HIMALAYA study of tremelimumab plus durvalumab in unresectable hepatocellular carcinoma (uHCC)
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
148P - Safety and efficacy of atezolizumab (Atezo) + bevacizumab (Bev) in Japanese patients (pts) with unresectable hepatocellular carcinoma (uHCC): Preliminary analysis of a prospective, multicenter, observational study (ELIXIR)
Presenter: Teiji Kuzuya
Session: Poster Display
Resources:
Abstract
149P - A prospective observational study of MSI screening in unresectable chemotherapy-naïve advanced gastric cancer/gastroesophageal junction cancer: WJOG13320GPS
Presenter: Yukiya Narita
Session: Poster Display
Resources:
Abstract
150P - Anlotinib plus chemotherapy as first-line therapy for gastrointestinal tumor patients with unresectable liver metastasis: Updated results from a multi-cohort, multi-center phase II trial ALTER-G-001-cohort C
Presenter: Junwei Wu
Session: Poster Display
Resources:
Abstract
151P - Relationship between depth of response and early tumor shrinkage with overall survival in advanced pancreatic cancer
Presenter: EMIKA KUROKI
Session: Poster Display
Resources:
Abstract
152P - Interim analysis of the NAPOLEON-2 study: Safety evaluation of nanoliposomal irinotecan with fluorouracil and folinic acid for unresectable pancreatic cancer patients with prior biliary drainage
Presenter: Futa Koga
Session: Poster Display
Resources:
Abstract